{
  "id": "df1a99a5-5c0e-4a69-969d-4388a7e4fa6a",
  "patient_id": "bc8a3bb5-01b7-4bbd-a79a-43f812620f3a",
  "encounter_id": "5f9f4650-7af0-451a-813d-6693489bdc44",
  "analysis_type": "Genetic Testing Recommendation",
  "input_text": "Patient: Steven Ortega, DOB: 2006-02-16, Gender: Male\n\nChief Complaint: headache\n\nS: Patient Describes no history of illness\n\nO: No physical exam documented.\n\nA: No assessment documented.\n\nP: No plan documented.\n\n--- IMAGING & SCANS ---\n- ECG (3/25/2025): ECG Scan for Patient\n\n--- IMAGING & SCANS ANALYSIS ---\n\n[Scan 1: ECG (2025-03-25T09:09:28.833517)]\nFile: norm.png\nDescription: ECG Scan for Patient\nAnalysis: Okay, let\u2019s analyze this ECG. Here's a detailed breakdown of what I see, incorporating relevant observations and potential concerns:\n\n**Overall Impression:**\n\nThe ECG shows a sinus rhythm, but there are several concerning findings that warrant immediate attention and further investigation.  The most prominent abnormality is a significant left ventricular hypertrophy (LVH). \n\n**Detailed Analysis \u2013 Waveform by Waveform:**\n\n* **Rate:** The heart rate appears to be approximately 75-80 beats per minute. This is within the normal range.\n* **Rhythm:** The rhythm is regular, indicating sinus rhythm.\n* **P Waves:** The P waves are present and generally upright in leads I, II, aVL, and V1-V6. However, they appear somewhat peaked and notched, particularly in V1 and V6, suggesting some degree of ventricular pre-excitation (WPW pattern, though not definitively confirmed).\n* **PR Interval:** The PR intervals are prolonged, consistently greater than 0.20 seconds (approximately). This prolongation is a key indicator of LVH.\n* **QRS Complex:** This is where the most significant abnormalities are present.\n    * **Width:** The QRS complexes are wide, consistently greater than 0.12 seconds. This is a hallmark of LVH.\n    * **Morphology:** The QRS complexes are predominantly positive in leads V1-V6, indicating right ventricular involvement. The Q waves are present but not excessively deep.\n* **ST Segment:** The ST segments are elevated, particularly in leads V1-V6, and in some cases, there is ST-segment depression. This is consistent with myocardial ischemia or injury.\n* **T Waves:** The T waves are generally inverted in the precordial leads (V1-V6), further supporting the presence of myocardial ischemia.\n* **QT Interval:** The QT intervals appear normal.\n\n**Specific Findings and Observations:**\n\n1. **Left Ventricular Hypertrophy (LVH):** This is the most significant finding. The prolonged PR intervals, wide QRS complexes, and ST-segment changes all point to LVH. The prominence of the Q waves in V1-V6 suggests the hypertrophy is more pronounced on the right side of the heart as well.\n\n2. **Possible Ventricular Pre-excitation (WPW):** The slightly peaked and notched P waves, particularly in V1 and V6, raise the possibility of a pre-excitation\n",
  "recommendation": "recommended",
  "reasoning": "The ECG shows significant left ventricular hypertrophy (LVH), a prominent finding that warrants immediate attention.  The wide QRS complexes, prolonged PR intervals, and ST-segment changes all strongly suggest LVH.  The presence of possible ventricular pre-excitation (WPW pattern, though not definitively confirmed) further complicates the picture.  Given the patient's age (19 years old at the time of the ECG), the severity of the LVH, and the potential for pre-excitation, several rare genetic diseases must be considered in the differential diagnosis.  These include, but are not limited to, arrhythmogenic right ventricular cardiomyopathy (ARVC), Brugada syndrome, long QT syndrome (LQTS), and hypertrophic cardiomyopathy (HCM).  The ECG findings are not entirely specific to any one condition, and overlap exists between these conditions.  The absence of a detailed medical history and physical exam makes it difficult to narrow down the possibilities.  Therefore, genetic testing is crucial to identify the underlying genetic cause of the LVH and associated abnormalities.  This testing could involve a multigene panel encompassing genes associated with the aforementioned conditions or even comprehensive genomic testing (exome or genome sequencing) to explore a broader range of possibilities.  The results of genetic testing will guide appropriate management and risk stratification for the patient.",
  "confidence": "75%",
  "model_used": "Gemini-Pro",
  "retrieved_docs": [
    {
      "id": "arvd_txt_5",
      "contents": "100\\,\\mathrm{mL}/\\mathrm{m}^{2}$ to $<\\!110\\;\\mathrm{mL}/\\mathrm{m}^{2}$ (male) or $\\geq\\!90\\;\\mathrm{mL}/\\mathrm{m}^{2}$ to ${<}100\\;\\mathrm{mL}/\\mathrm{m}^{2}$ (female) \u25aa RV ejection fraction ${>}40\\%$ to ${\\le}45\\%$ \nEndomyocardial Biopsy or Autopsy Findings \nMajor. Residual myocytes ${<}60\\%$ by morphometric analysis (or ${<}50\\%$ if estimated), with fbrous replacement of the RV free wall myocardium in at least one sample, with or without fatty replacement of tissue \nMinor. Residual myocytes $60\\%-75\\%$ by morphometric analysis (or $50\\%{-}65\\%$ if estimated), with fbrou s replacement of the RV free wall myocardium in at least one sample, with or without fatty replacement of tissue \nEKG Findings \nRepolarization abnormalities \n\u2022 Major. Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in individuals age ${>}14$ years (in the absence of complete right bundle branch block $\\mathrm{QRS}\\,{\\geq}120~\\mathrm{ms})$ \n\u2022 Minor \u26ac Inverted T waves in leads V1 and V2 in individuals age ${>}14$ years (in absence of complete right bundle branch block) or in V4, V5, or V6 \u26ac Inverted T waves in leads V1, V2, V3, and V4 in individuals age ${>}14$ years in the presence of complete right bundle branch block \nDepolarization/conduction abnormalities \n\u2022 Major. Epsilon waves (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V1 to V3)   \n",
      "token_count": 468,
      "sentence_count": 12
    },
    {
      "id": "barth_txt_9",
      "contents": " Spencer et al [2006] observed that with standard cardiac medications for dilated cardiomyopathy more than 16/30 afected males had normal ejection fraction and lef ventricular diastolic volume. However, some responded to therapy initially but deteriorated afer a period of stability, requiring cardiac transplantation [Adwani et al 1997, Mangat et al 2007]. \nArrhythmia. Te risk for arrhythmia (including supraventricular and ventricular tachycardia) and sudden death is increased. While arrhythmia has been most ofen reported in adolescents and young adults, it can occur in children of all ages. EKG abnormalities can include repolarization abnormalities and prolonged QTc intervals. \nAll 20 afected males with EKGs in the French cohort had a normal sinus rhythm. Repolarization abnormalities (including ST fattening and T-wave inversion) were seen in 17. Five had QTc values within the normal range (QTc ${<}420\\;\\mathrm{ms}_{}$ ), and fve had QTc greater than $460\\:\\mathrm{ms}$ . Te median QTc was $440\\:\\mathrm{ms}$ (range: $360{-}530~\\mathrm{ms})$ ). In the study by Kang et al [2016], nine of 21 afected individuals had prolonged QTc of greater than $460~\\mathrm{ms}$ and three had borderline QTc prolongation between 450 and $460~\\mathrm{ms}$ . \nIn fve instances of ventricular arrhythmia leading to cardiac arrest or placement of an internal defbrillato r [Spencer et al 2005]: \n\u2022 All fve individuals had normal QTc intervals;   \n\u2022 All fve had a history of recurrent vasovagal symptoms including postural dizziness, nausea, and pallor suggestive of autonomic instability;   \n\u2022 Four had only mild LV dilatation and low normal to mildly depressed LV function; only one had poor but stable LV function prior to cardiac arrest;   \n\u2022 Tree showed inducible ventricular arrhythmias on electrophysiologic testing;   \n",
      "token_count": 479,
      "sentence_count": 15
    },
    {
      "id": "brugada_txt_11",
      "contents": "Note: Data on genetic modifers (e.g., susceptibility loci / polymorphisms identifed through genome-wide association studies) in Brugada syndrome-related genes that may contribute in small ways to risk of a given phenotype are not included in Table 2. \nDifferential Diagnosis \nBrugada syndrome should always be considered in the diferential diagnosis of the following: \n\u2022 Sudden cardiac death and syncope in persons with a structurally normal heart   \n\u2022 SIDS. Brugada syndrome does not usually cause problems at such a young age; however, SCN5A pathogenic variants have been described in a few infants with SIDS. SIDS is believed to be etiologically and genetically heterogeneous [Weese-Mayer et al 2007] with an unknown proportion attributed to Brugada syndrome.   \n\u2022 Sick sinus syndrome. Brugada syndrome could be observed in persons with sick sinus syndrome given the defects observed in cardiac conduction [Nakazato et al 2004]. \nOther conditions that can be associated with ST segment elevation in right precordial leads include the following (adapted from de Oliveira Neto et al [2019] and Wilde et al [2002] with permission). \nAbnormalities that can lead to ST segment elevation in the right precordial leads \n\u2022 Right or lef bundle branch block, lef ventricular hypertrophy   \nAcute myocardial ischemia or infarction   \nAcute myocarditis Hypothermia, causing Osborn wave in EKGs and sometimes resembling Brugada syndrome Right ventricular ischemia or infarction Dissecting aortic aneurysm Acute pulmonary thromboemboli Various central and autonomic nervous system abnormalities Heterocyclic antidepressant overdose Duchenne muscular dystrophy Friedreich ataxia Tiamine defciency   \n\u2022 Hypercalcemia   \nHyperkalemia   \n\u2022 Cocaine intoxication \nMediastinal tumor compressing the right ventricular outfow tract Arrhythmogenic right ventricular cardiomyopathy \nOther conditions that can lead to ST segment elevation in the right precordial leads \nEarly repolarization syndrome Other normal variants (particularly in males) \nMost of the above conditions can give rise to a type 1 EKG, whereas ARVC and Brugada syndrome can both give rise to type 2 and type 3 EKGs.",
      "token_count": 490,
      "sentence_count": 21
    },
    {
      "id": "brugada_txt_5",
      "contents": " Sequence analysis of the gene of interest is performed frst, followed by genetargeted deletion/duplication analysis if no pathogenic variant is found. \n\nA multigene panel that includes the genes listed in Table 1 and other genes of interest (see Diferenti al Diagnosis) may also be considered to identify the genetic cause of the condition while limiting identifcation of variants of uncertain signifcance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) Te genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specifed by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests. \nFor an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here. \nOption 2 \nComprehensive genomic testing does not require the clinician to determine which gene is likely involved.   \nExome sequencing is most commonly used; genome sequencing is also possible. \nFor an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here. \nAAD: antiarrhythmic drugs   \nANS: autonomic nervous system   \nARVC/D: arrhythmogenic right ventricular cardiomyopathy/dysplasia   \nBS: Bpugada syndrome   \nCNS: central nervous system   \nECG: elecrocardiogram   \nLVH: left ventricularhypertrophy   \nMl: myocardial infarction   \nPVT: polymorphicventricular tachycardia   \nRBBB: right ventricular bundle branch block   \nRVMI: right ventricular myocardial infarction   \nRVOT: right ventricular outflow tract   \nSCD: sudden cardiac death   \nVF: ventricular fibrillation \nReproduced from Berne & Brugada [2012] with permission \n1. See Table A.",
      "token_count": 476,
      "sentence_count": 28
    },
    {
      "id": "thompson_thompson_genetics_8th_edition_medicoscompanion_com_txt_767",
      "contents": "LQT syndrome is caused by repolarization defects in cardiac cells. Repolarization is a controlled process that requires a balance between inward currents of sodium and calcium and outward currents of potassium. Imbalances cause the action potential of cells to increase or decrease in duration, causing elongation or shortening, respectively, of the QT interval on electrocardiography. Most cases of LQT syndrome are caused by loss-of-function mutations in genes that encode subunits or regulatory proteins for potassium channels (genes whose names begin with KCN). These mutations decrease the outward, repolarization current, thereby prolonging the action potential of the cell and lowering the threshold for another depolarization. In other LQT syndrome patients, gain-of-function mutations in a sodium channel gene, SCN5A, lead to an increased influx of sodium, resulting in similar shifting of action potential and repolarization effects. \nPhenotype and Natural History \nThe LQT syndromes are characterized by elongated QT interval and T-wave abnormalities on electrocardiography (Fig. C-28), including tachyarrhythmia and torsades de pointes, a ventricular tachycardia characterized by a change in amplitude and twisting of the QRS complex. Torsades de pointes is associated with a prolonged QT interval and typically stops spontaneously but may persist and worsen to ventricular fibrillation. \n\nIn the most common LQT syndrome, Romano-Ward, syncope due to cardiac arrhythmia is the most frequent symptom; if undiagnosed or left untreated, it recurs and can be fatal in $10\\%$ to $\\bar{1}5\\%$ of cases. However, between $30\\%$ and $50\\%$ of individuals with the syndrome never show syncopal symptoms. Cardiac episodes are most frequent from the preteen years through the 20s, with the risk decreasing over time. Episodes may occur at any age when triggered by QTprolonging medications (see list at http://www.qtdrugs.org). Nonpharmacological triggers for cardiac events in the Romano-Ward syndrome differ on the basis of the gene responsible. LQT1 triggers are typically adrenergic stimuli, including exercise and sudden emotion.",
      "token_count": 492,
      "sentence_count": 16
    },
    {
      "id": "cvt_txt_3",
      "contents": "\u2022 History of exercise- or emotion-related palpitations and dizziness in some individuals   \n\u2022 Sudden unexpected cardiac death triggered by acute emotional stress or exercise   \n\u2022 Family history of juvenile sudden cardiac death triggered by exercise or acute emotion   \n\u2022 Exercise-induced bidirectional or polymorphic ventricular arrhythmias \u26ac EKG during a graded exercise (exercise stress test) \\* allows ventricular arrhythmias to be reproducibly elicited in the majority of afected individuals. Typically, the onset of ventricular arrhythmias is 90-120 beats per minute. \u26ac With increase in workload, the complexity of arrhythmias progressively increases from isolated premature beats to bigeminy and runs of non-sustained ventricular tachycardia (VT). If the afecte d individual continues exercising, the duration of the runs of VT progressively increases and VT may become sustained. \u26ac An alternating $180^{\\circ}$ -QRS axis on a beat-to-beat basis, so-called bidirectional VT, is ofen the distinguishing presentation of CPVT arrhythmias [Priori et al 2021]. \u26ac Notably, some individuals with CPVT may also present with irregular polymorphic VT without a \"stable\" QRS vector alternans [Swan et al 1999, Priori et al 2002]. \u26ac Exercise-induced supraventricular arrhythmias (supraventricular tachycardia and atrial fbrillatio n) are common [Leenhardt et al 1995, Fisher et al 1999]. \n\u2022 Ventricular fbrillation occurring in the setting of acute stress \\* Note: Te resting EKG of individuals with CPVT is usually normal. Some authors have reported a lower-thannormal resting heart rate [Postma et al 2005] and others have observed a high incidence of prominent U waves, particularly in the precordial leads [Leenhardt et al 1995, Aizawa et al 2006]. Overall, these features are inconsistent and not sufciently specifc to allow diagnosis. Terefore, in many instances the origin of the syncope may be erroneously attributed to a neurologic disorder. Te exercise stress test is the single most important diagnostic test.",
      "token_count": 485,
      "sentence_count": 15
    },
    {
      "id": "arvd_txt_6",
      "contents": "\u2022 Minor \u26ac Late potential by signal-averaged EKG in at least one of three parameters in the absence of a QRS duration of ${\\geq}110~\\mathrm{ms}$ on standard EKG \u26ac Filtered QRS duration $(\\mathrm{fQRS})\\,{\\geq}114\\,\\mathrm{ms}$ $^\\circ$ Duration of terminal QRS ${<}40\\,\\mathrm{uV}$ (low-amplitude signal duration) ${\\geq}38$ ms \u26ac Root-mean-square voltage of terminal $40\\;\\mathrm{ms}\\leq20\\;\\mathrm{uV}$ \n\u26ac Terminal activation duration of $\\mathrm{QRS}>55~\\mathrm{ms}$ measured from the nadir of the S wave to the end of the QRS, including $\\mathrm{R}^{\\prime}$ , in V1, V2, or V3 in the absence of complete right bundle branch block \nArrhythmias \n\u2022 Major. Nonsustained or sustained ventricular tachycardia of lef bundle branch morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)   \n\u2022 Minor \u26ac Nonsustained or sustained ventricular tachycardia of RV outfow confguration, lef bundle branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis \u26ac ${>}500$ ventricular extrasystoles per 24 hours (Holter) \nFamily History and Molecular Genetic Testing \nMajor \n\u2022 ARVC confrmed in a frst-degree relative who meets 2010 Task Force Criteria [Marcus et al 2010] \u2022 ARVC confrmed pathologically at autopsy or surgery in a frst-degree relative \u2022 Identifcation of a pathogenic variant categorized as associated or probably associated with ARVC in the proband \nMinor \n",
      "token_count": 433,
      "sentence_count": 6
    },
    {
      "id": "arvd_txt_1",
      "contents": "Note: Tere is a movement within clinical cardiology to merge ARVC with other arrhythmogenic cardiomyopathies because the lef ventricle can become involved, or even become predominantly involved, especially in individuals with $D S P$ pathogenic variants; lef ventricular involvement has also been reported in individuals with variants in genes encoding other desmosomal proteins (e.g., DSC2) that were previously associated with ARVC. Te 2010 Task Force Criteria (see Diagnosis) are still used to establish a clinical diagnosis of ARVC [Marcus et al 2010], and these criteria do not incorporate other arrhythmogenic cardiomyopathies, leading to potential underdiagnosis. An international expert panel convened to reevaluate the diagnostic approach to arrhythmogenic cardiomyopathies and developed new criteria, the Padua Criteria [Corrado et al 2020]. Tere are ongoing studies to evaluate the proposed Padua Criteria in larger cohorts. Readers should be aware of the potential overlap/diferentiation between ARVC and other arrhythmogenic cardiomyopathies. \ndescribed stages of ARVC are the following [Te Riele et al 20 \n1. Te concealed phase is the earliest phase and is without electrical, structural, or histologic changes as typically seen in ARVC. If scar formation is present, it can be so minimal that it goes undetected by cardiac MRI. However, afected individuals might experience sustained ventricular arrhythmias, and there is a potential risk of sudden cardiac death.   \n2. An overt electrical disorder characterized by symptomatic arrhythmias including palpitations, syncope, and presyncope attributable to ventricular ectopy or sustained or nonsustained ventricular tachycardia   \n3. Right ventricular failure   \n4. A biventricular pump failure (resembling dilated cardiomyopathy) [Dalal et al 2006] \nCardiomyopathy in ARVC is not always isolatedto right ventricular involvement. Tere is evidence that the  lef ventricle can ofen become involved as well.",
      "token_count": 454,
      "sentence_count": 15
    },
    {
      "id": "rws_txt_7",
      "contents": "stablishing a specifc genetic cause of long QT syndrome (LQ \u2022 Can aid in discussions of prognosis (which are beyond the scope of this GeneReview) and genetic counseling; \u2022 Usually involves a medical history, physical examination, family history, and genomic/genetic testing. \n\nClinical history. Clinical history in individuals with syncope or a cardiac arrest can reveal specifc triggers for the cardiac event that can be gene specifc. On rare occasions LQTS is accompanied by gene-spe cifc extracardiac features. \nPhysical examination. Te great majority of individuals with LQTS do not have associated physical features. On rare occasions, LQTS is accompanied by gene-specifc extracardiac features. Individuals with EKG characteristics suggestive of a specifc LQTS-associated syndrome (e.g., EKG with T-U patterns characteristic of Andersen-Tawil syndrome) can be assessed for physical features of that syndrome. \nFamily history. A three-generation family history should be taken, with attention to relatives with manifestations of LQTS \u2013 including syncope, aborted cardiac arrest, or sudden death in a child or (young) adult \u2013 and documentation of relevant fndings through direct examination or review of medical records, including results of molecular genetic testing and EKG recordings. Specifc focus should also be on triggers of events in relatives, as well as epilepsy (LQTS-associated syncopes may have been attributed to epilepsy). In such instances, review of medical records should include EEG recordings, accompanied by an EKG, which can show QTc prolongation in afected family members. \nEKG evaluation. Te corrected QT (QTc) values on resting EKG and ST-T wave morphology can suggest a specifc genetic cause of LQTS (see Table 2). Additional tests can be helpful to unmask QTc prolongation in individuals with borderline QTc values on resting EKG [Priori et al 2013]: \n\u2022 Exercise EKG, which commonly shows failure of the QTc to shorten normally and even prolongation of the QTc interval [Jervell & Lange-Nielsen 1957, Vincent et al 1991, Swan et al 1998, Horner et al 2011, Sy et al 2011].",
      "token_count": 484,
      "sentence_count": 17
    },
    {
      "id": "rws_txt_1",
      "contents": " Tis idea is incorporated in the LQTS diagnostic scoring system proposed in the European Society of Cardiology guidelines for management of LQTS [Zeppenfeld et al 2022] (see Table 1). A LQTS risk score of $>\\!3.0$ in the absence of a secondary cause for QT prolongation is sufcient for a diagnosis of LQTS. \nCardiac Features \nT wave abnormalities include T wave alternans, notched T wave, broad-based and fattened T waves (see Adler et al [2020] and Wilde et al [2022] for concise examples and Tardo et al [2023] for a comprehensive review) and are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is \nusually self-terminating and may cause palpitations, dizziness, or syncope, the most common symptom in individuals with LQTS. Syncope is typically precipitous and without warning. A careful evaluation of medical history can help distinguish LQTS-associated syncope from common vasovagal and orthostatic forms of syncope in which presyncope and other warning symptoms occur. Absence of aura, incontinence, and postictal fndings help diferentiate LQTS-associated syncope from seizures. Te number of syncopal events in symptomatic individuals ranges from one to hundreds, averaging just a few. In some instances, TdP degenerates to ventricular fbrillation and aborted cardiac arrest (if the individual is defbrillated) or sudden death. \nCardiac events (i.e., syncope, cardiac arrest, or sudden cardiac death) may occur from infancy through middle age but are most common from the preteen years through the 20s, with the risk generally diminishing throughout that time period. Te usual age range of events difers somewhat for each genotype. Cardiac events are uncommon afer age 40 years; when present, they are ofen triggered by administration of a QT-prolonging drug or hypokalemia. Cardiac events in individuals over age 40 years are more likely associated with SCN5Arelated LQTS. \n",
      "token_count": 479,
      "sentence_count": 16
    },
    {
      "id": "salih-myo_txt_1",
      "contents": "Agents/circumstances to avoid: Ibuprofen in those with congestive heart failure. \nGenetic counseling \nSalih myopathy is inherited in an autosomal recessive manner. Te parents of an afected child are obligate heterozygotes (i.e., carriers of one pathogenic variant) and are asymptomatic. At conception, each sib of an afected individual has a $25\\%$ chance of being afected, a $50\\%$ chance of being an asymptomatic carrier, and a $25\\%$ chance of being unafected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for a pregnancy at increased risk are possible if the pathogenic variants in the family have been identifed. \nDiagnosis \nSuggestive Findings \nSalih myopathy should be suspected in individuals with the following clinical, laboratory, electrophysiologic, imaging, and histopathology fndings. \nClinical \n\u2022 Muscle weakness manifesting during the neonatal period or in early infancy   \n\u2022 Delayed motor milestones but normal cognitive development   \n\u2022 Muscle weakness of limb-girdle distribution, myopathic face, variable degree of ptosis, and relative calf muscle hypertrophy   \n\u2022 Development of dilated cardiomyopathy between ages fve and 16 years   \n\u2022 Major heart rhythm disturbances leading to sudden death before age 20 years \nm creatine kinase (CK) is marginally to moderately increase \nElectrophysiologic \n\u2022 Electrocardiography. Lef axis deviation (lef anterior fascicular block) can be seen as early as age four years (Figure 1). With the onset of dilated cardiomyopathy, rhythm disturbances can include polymorphic premature ventricular complexes, bigeminism and trigeminism, couplets, triplets, atrioventricular heart block, atrioventricular nodal reentrant tachycardia, premature atrial complexes, premature ventricular complexes, and ventricular tachycardia.   \n\u2022 Electromyography shows myopathic features (low-amplitude polyphasic potentials of short duration).   \n\u2022 Nerve conduction studies are normal. \n",
      "token_count": 452,
      "sentence_count": 21
    },
    {
      "id": "fabry_txt_12",
      "contents": " Echocardiography demonstrates an increased thickness of the interventricular septum and the lef ventricular posterior wall [Yeung et al 2018]. Magnetic resonance studies using gadolinium demonstrated late enhancement areas, corresponding to myocardial fbrosis and associated with decreased regional functioning as assessed by strain and strain-rate imaging [Weidemann et al 2005]. $\\mathrm{T}_{1}$ mapping illustrates intramural fat deposition and posterior wall fbrosis [Sado et al 2013, Augusto et al 2021] which occurs prior to LVH. It has been hypothesized that a pre-storage myocardial phenotype might occur prior to $\\mathrm{T}_{1}$ lowering with microvascular dysfunction, impaired global longitudinal strain, and altered atrial depolarization and ventricular repolarization intervals [Augusto et al 2021]. \nAmong 714 predominantly adult individuals in the FOS [Linhart et al 2007], angina, palpitations/arrhythmia, and exertional dyspnea were found in $23\\%{-}27\\%$ of males and $22\\%{-}25\\%$ of females. Hypertension, angina pectoris, myocardial ischemia and infarction, congestive heart failure, and severe mitral regurgitation are late signs. Hypertension was found in more than $50\\%$ of males and more than $40\\%$ of females in the FOS [Kleinert et al 2006]. \nCerebrovascular manifestations result primarily from multifocal small vessel involvement and may include thrombosis, transient ischemic attacks (TIA), basilar artery ischemia and aneurysm, seizures, hemiplegia, hemianesthesia, aphasia, labyrinthine disorders, or frank cerebral hemorrhage [Burlina & Politei 2016]. Individuals with Fabry disease had increased basilar artery mean diameter and basilar artery linear length compared with controls [Fellgiebel et al 2011, Manara et al 2017]. White matter lesions are frequently found on MRI of individuals with Fabry; age and prior stroke independently predicted the burden of white matter hyperintensities [Rost et al 2016, K\u00f6rver et al 2020b]. \nRenal involvement.",
      "token_count": 500,
      "sentence_count": 11
    },
    {
      "id": "thompson_thompson_genetics_8th_edition_medicoscompanion_com_txt_754",
      "contents": " C-25) in the absence of predisposing cardiac conditions (e.g., aortic stenosis) or cardiovascular conditions (e.g., longstanding hypertension). The clinical manifestations of HCM range from asymptomatic to progressive heart failure to sudden cardiac death and vary from individual to individual even within the same family. Common symptoms include shortness of breath (particularly with exertion), chest pain, palpitations, orthostasis, presyncope, and syncope. Most often the LVH of HCM becomes apparent during adolescence or young adulthood, although it may also develop late in life, in infancy, or in childhood. \n\nManagement \nBefore identification of the genes responsible for HCM, diagnosis of HCM could only be made through integration of examination, electrocardiogram, echocardiogram, and invasive angiographic/hemodynamic studies, disproportionately identifying patients with left ventricular outflow obstruction. Genetic testing for HCM is now available and can provide important insights into family management by definitively identifying at-risk relatives (i.e., those who have inherited the family\u2019s pathogenic mutation). Mutations found are considered pathogenic based on the following criteria: (1) cosegregation with the HCM phenotype in family members; (2) previously reported or identified as a cause of HCM; (3) absent from unrelated and ethnic-matched normal controls; (4) important alteration in protein structure and function; and (5) amino acid sequence change in a region of the protein otherwise highly conserved through evolution. However, even with the use of these criteria, a considerable number of variants are classified as VUSs (see Chapter 16), making the test results ambiguous. \nBecause diagnosis and sudden cardiac death risk are both linked to the presence of LVH and because the penetrance of LVH is age-dependent, clinical evaluation must continue longitudinally. Screening is annual during adolescence and early adulthood when LVH most commonly emerges. Early childhood screening is appropriate if there is a family history of early-onset disease or other concerns. During adulthood, screening is recommended approximately every $5$ years or in response to clinical changes because LVH can develop late in life.",
      "token_count": 473,
      "sentence_count": 15
    },
    {
      "id": "friedreich_txt_9",
      "contents": " A longitudinal study identifed two groups; a \"low risk\" group (approximately $80\\%$ ) with normal ejection fraction that declined slowly and remained in the normal range and a \"high risk\" group (approximately $20\\%$ ) in whom ejection fraction declined into the abnormal range and was associated with high mortality [Pousset et al 2015]. Tose in the \"high risk\" group had longer GAA expansions on the shorter allele. Te degree of neurologic impairment did not predict whether an afected individual would have stable or rapid progression of cardiomyopathy. \nElectrocardiography (EKG) is abnormal in the vast majority, with T wave inversion, lef axis deviation, and repolarization abnormalities being most commonly seen [Dutka et al 1999]. \nSymptoms related to cardiomyopathy usually occur in the later stages of the disease [Dutka et al 1999] but in rare instances may precede ataxia [Alika\u015fifoglu et al 1999, Leonard & Forsyth 2001]. Quercia et al [2010] established the diagnosis of FRDA in a young child evaluated for sudden death. Subjective symptoms of exertional dyspnea $(40\\%)$ , palpitations $(11\\%)$ , and anginal pain may be present in moderately advanced disease. Arrhythmias (especially atrial fbrillation) and congestive heart failure frequently occur in the later stages of the disease and are the most common cause of mortality [Tsou et al 2011]. Coronary artery disease may occur and should be considered if there is angina and/or sudden deterioration in cardiac function [Giugliano & Sethi 2007]. \nUrinary issues. Bladder symptoms including urinary frequency and urgency were reported by $41\\%$ of individuals in one study [Delatycki et al 1999a]. A study of 158 individuals with FRDA revealed lower urinary tract symptoms in $82\\%$ with impact on quality of life in $22\\%$ of those [Musegante et al 2013]. Of 28 who underwent urodynamic studies, all had normal serum creatinine and four had upper urinary tract dilatation. \nSleep-disordered breathing.",
      "token_count": 479,
      "sentence_count": 14
    },
    {
      "id": "jln_txt_11",
      "contents": " For a complete, updated list see www.crediblemeds.org (registration required).   \n\u2022 Primary myocardial problems: cardiomyopathy, myocarditis, ischemia   \n\u2022 Central nervous or autonomic system injury; subarachnoid hemorrhage; stellate ganglion blockade \nHearing loss. Te diferential diagnosis for hearing loss includes consideration of other forms of syndromic and nonsyndromic disorders, as well as acquired disorders. For more information on hereditary hearing loss, see Genetic Hearing Loss Overview. \nOne disorder that should be noted specifcally is DFNB1, the most common autosomal recessive form of nonsyndromic hearing loss. DFNB1 is characterized by congenital, non-progressive, mild-to-profound sensorineural hearing impairment. No other associated medical fndings are present. Diagnosis of DFNB1 depends on molecular genetic testing to identify biallelic pathogenic variants in GJB2 (sequence variants as well as variants in upstream cis-regulatory elements that alter expression of the gap junction beta-2 protein [connexin 26]). JLNS should be suspected in any infant who has profound bilateral sensorineural hearing loss, no identifable GJB2 pathogenic variants, and a normal physical examination. \nBrugada syndrome is characterized by cardiac conduction abnormalities (ST-segment abnormalities in leads V1-V3 on EKG and a high risk for ventricular arrhythmias) that can result in sudden death. \nSudden infant death syndrome (SIDS) (OMIM 272120). Data from multicenter studies indicate that $9.5\\%$ of infants with SIDS may be heterozygous for functionally signifcant variants in one of the known LQTS-related genes. Sudden arrhythmic death may thus be an important contributor to SIDS; it is unknown what proportion of infants with SIDS have or would develop profound hearing impairment. Implementation of universal neonatal hearing screening, supplemented with early electrocardiography, may have the potential to identify high-risk children. However, a recent large population study did not fnd a higher incidence of JLNS in newborns identifed with hearing loss by universal screening [Chang et al 2014]. \nManagement \nEvaluations Following Initial Diagnosis \n",
      "token_count": 489,
      "sentence_count": 21
    },
    {
      "id": "hyper-card_txt_20",
      "contents": " Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med. 2013;15:972-7. PubMed PMID: 23598715.   \nLorenzini M, Norrish G, Field E, Ochoa JP, Cicerchia M, Akhtar MM, Syrris P, Lopes LR, Kaski JP, Elliott PM. Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers. J Am Coll Cardiol. 2020;76:550-9. PubMed PMID: 32731933.   \nMaron BJ (2003) Sudden death in young athletes. N Engl J Med 349:1064-75 PubMed PMID: 12968091.   \nMaron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F (2000) Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102:858-64. PubMed PMID: 10952953.   \nMaron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ (2003) Efect of  lef ventricular outfow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295-303 PubMed PMID: 12540642.   \nNagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, Quinones MA, Roberts R, Marian AJ (2001) Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 104:128-30 PubMed PMID: 11447072.   \nNiimura H, Patton KK, McKenna WJ, Soults J, Maron BJ, Seidman JG, Seidman CE (2002) Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 105:446-51 PubMed PMID: 11815426.   \n",
      "token_count": 486,
      "sentence_count": 19
    },
    {
      "id": "dcm-lmna_txt_5",
      "contents": " In another retrospective study of 122 individuals with LMNA pathogenic variants, of those who had preserved lef ventricular function and no heart failure at the time of presentation, new-onset lef ventricular dysfunction or heart failure was observed in ${\\sim}24\\%$ and $7\\%$ of individuals, respectively, afer seven years [Kumar et al 2016]. \n\u2022 Conduction system involvement usually starts with disease of the sinus node and/or atrioventricular node that can manifest as sinus bradycardia, sinus node arrest with junctional rhythms, or heart block (commonly frst-degree heart block that progresses to second- and third-degree block). Te following are also common: \n\u26ac Symptomatic bradyarrhythmias requiring cardiac pacemakers   \n\u26ac Supraventricular arrhythmias including atrial futter, atrial fbrillation, supraventricular tachycardia, and the sick sinus syndrome (i.e., tachycardia-bradycardia syndrome)   \n\u26ac Ventricular arrhythmias including frequent premature ventricular contractions, ventricular tachycardia, and ventricular fbrillation \n\u2022 Sudden cardiac death may occur with progressive disease. Although more malignant, life-threatening arrhythmias may occur with longstanding and usually previously symptomatic DCM, sudden cardiac \ndeath can also be the presenting manifestation of LMNA-related DCM, with minimal or no  lef ventricular dysfunction [Meune et al 2006].   \n\u2022 Variable DCM. Only mild-to-moderate lef ventricular dilatation despite progressive disease has been noted by some investigators. Terefore, LMNA-related DCM may be an appropriate diagnosis in those with an LMNA pathogenic variant who have clinical conduction system disease and/or arrhythmia prior to the lef ventricular enlargement or with minimal or no systolic dysfunction.   \n\u2022 Skeletal muscle disorder. Occasionally, individuals with LMNA-related cardiomyopathy also manifest signs or symptoms of skeletal myopathy, which may be associated with elevated serum creatine kinase concentration. \nLarge prospective longitudinal studies to defne the range of natural history of individuals with LMNA pathogenic variants have not yet been published. \n",
      "token_count": 492,
      "sentence_count": 16
    },
    {
      "id": "thompson_thompson_genetics_8th_edition_medicoscompanion_com_txt_753",
      "contents": " The cardiologist explained to the patient the possibility of hypertrophic cardiomyopathy running in his family. Cardiac examination showed double apical impulse and laterally displaced, split second heart sound, fourth heart sound present, jugular venous pulse, and double carotid arterial pulse. Echocardiogram showed asymmetrical septal hypertrophy with no structural anomalies, diagnostic of hypertrophic cardiomyopathy. Consistent with his clinical history, physical features, and family history, DNA testing identified an Arg403Gln mutation in MYH7. \nBACKGROUND \nDisease Etiology and Incidence \nHypertrophic cardiomyopathy (HCM, MIM 192600), the most common monogenic cardiovascular disease, is an autosomal dominant disorder caused by mutations in approximately 20 genes encoding proteins of the cardiac sarcomere. Of those patients with positive genetic tests, approximately $70\\%$ are found to have mutations in the two most common genes, MYH7 and MYBPC3, whereas other genes, including those encoding troponin T, troponin I, Tropomyosin 1, and alpha-actin each account for a small proportion of patients ( $1\\%$ to $5\\,\\%$ ). \nPathogenesis \nOver 1500 mutations have been reported in genes encoding thick and thin myofilament proteins of the sarcomere or contiguous $Z$ disk. Mutations in several additional sarcomere (or calcium-handling) genes have been proposed, but with less evidence supporting pathogenicity. \nApproximately $60\\%$ of adult and pediatric patients with a family history of HCM will have a sarcomere mutation identified. In contrast, only approximately $30\\%$ of patients without a family history will have positive results, often due to sporadic or de novo mutations ( $65\\%$ of the probands) that may, however be passed on to the next generation. Approximately \n$3\\,\\%$ to $4\\%$ of males with HCM will have unrecognized Fabry disease, a lysosomal storage disorder caused by mutations in the $\\upalpha$ galactosidase A gene. \nPhenotype and Natural History \nHCM is characterized by left ventricular hypertrophy (LVH) (Fig.",
      "token_count": 481,
      "sentence_count": 16
    },
    {
      "id": "hyper-card_txt_12",
      "contents": " Clinical cardiovascular screening by physical examination, EKG, and echocardiography should be performed in accordance with published recommendations [Ommen et al 2020] in all asymptomatic frst-degre e relatives (adults and children) of an individual with HCM in whom a pathogenic variant has not been identife d (see Table 4b). \n\nBecause penetrance of diagnostic features (i.e., LVH) is age dependent, a single unremarkable evaluation does not exclude the possibility of future development of HCM. Diagnostic clinical manifestations are ofen not present in infancy / early childhood; they commonly develop during adolescence and early adulthood, but may also develop late in life. Terefore, longitudinal follow up is required at a frequency based on the individual's age and family history and physician discretion. Screening should be performed in response to any symptoms that develop or any change in clinical status. \nNote: As understanding of human DNA variation evolves, it is possible that the classifcation of a variant will change, potentially afecting the recommendations made to a person/family. It is recommended that families of individuals with HCM follow up with a cardiovascular genetics clinic and/or genetic counselor on a regular basis as genetic testing methods improve. \nResources \nGeneReviews staf has selected the following disease-specifc and/or umbrella support organizations and/or registries for the beneft of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here. \nChildren's Cardiomyopathy Foundation Phone: 866-808-2873 (toll-free) Fax: 201-227-7016 Email: info@childrenscardiomyopathy.org www.childrenscardiomyopathy.org \nHypertrophic Cardiomyopathy Association (HCMA)   \n328 Green Pond Road   \nPO Box 306   \nHibernia NJ 07842   \nPhone: 973-983-7429   \nFax: 973-983-7870   \nEmail: support@4hcm.org \nwww.4hcm.org \nAmerican Heart Association (AHA)   \n7272 Greenville Avenue   \nDallas TX 75231   \nPhone: 800-242-8721 (toll-free)   \nEmail: review.personal.info@heart.org   \n",
      "token_count": 482,
      "sentence_count": 24
    },
    {
      "id": "hyper-card_txt_1",
      "contents": "\u2022 Findings on transthoracic echocardiography may also include: \u26ac Systolic anterior motion (SAM) of the mitral valve with associated lef ventricular outfow tract obstruction and mitral regurgitation; \u26ac Mid-ventricular obstruction as a result of systolic cavity obliteration; \u26ac Diastolic dysfunction, including restrictive physiology. Of note, impaired LV relaxation can be detected in individuals with a pathogenic variant in a gene that encodes a component of the sarcomere (see Nonsyndromic HCM) who have normal LV wall thickness [Nagueh et al 2001, Ho et al 2002], suggesting that diastolic dysfunction is an early phenotype of HCM rather than a secondary consequence of LVH. \nAlthough LVH and a clinical diagnosis of HCM ofen become apparent during adolescence around the onset of puberty or during young adulthood, onset can be earlier (in infancy and childhood) or later in life [Niimura et al 2002]. Common symptoms include shortness of breath (particularly with exertion), chest pain, palpitations, orthostasis, presyncope, and syncope. \nVariability and progression. Te clinical manifestations of HCM are highly variable, ranging from asymptomatic LVH to arrhythmias (atrial fbrillation as well as malignant ventricular arrhythmias) to refractory heart failure. Moreover, manifestations can vary even within the same family. \nApproximately one third of persons with HCM have detectable intracavitary obstruction at rest, and another third of persons with HCM can develop outfow tract obstruction with provocation (e.g., reduction of preload or aferload) [Maron et al 2003, Elliott et al 2014]. Te degree of obstruction does not strictly correlate with the severity of symptoms or risk for sudden cardiac death. Observational studies have reported that persons with HCM with outfow tract obstruction may be at higher risk for symptom progression and death than those without outfow tract obstruction [Maron et al 2003, Sorajja et al 2009]; high gradients may also be well tolerated over long periods of time. \n",
      "token_count": 471,
      "sentence_count": 11
    },
    {
      "id": "brugada_txt_32",
      "contents": " Manifestation of Brugada syndrome afer pacemaker implantation in a patient with sick sinus syndrome. J Cardiovasc Electrophysiol. 2004;15:1328\u201330. PubMed PMID: 15574187.   \nNamiki T, Ogura T, Kuwabara Y, et al. Five-year mortality and clinical characteristics of adult subjects with right bundle branch block and ST elevation. Circulation. 1995;93:334.   \nNunn L, Bhar-Amato J, Lambiase P. Brugada syndrome: controversies in risk stratifcation and management. Indian Pacing Electrophysiol J. 2010;10:400\u20139. PubMed PMID: 20930958.   \nOe H, Takagi M, Tanaka A, Namba M, Nishibori Y, Nishida Y, Kawarabayashi T, Yoshiyama M, Nishimoto M, Tanaka K, Yoshikawa J. Prevalence and clinical course of the juveniles with Brugada-type ECG in Japanese population. Pacing Clin Electrophysiol. 2005;28:549\u201354. PubMed PMID: 15955188.   \nOhno S, Zankov DP, Ding WG, Itoh H, Makiyama T, Doi T, Shizuta S, Hattori T, Miyamoto A, Naiki N, Hancox JC, Matsuura H, Horie M. KCNE5 (KCNE1L) variants are novel modulators of Brugada syndrome and idiopathic ventricular fbrillation. Circ Arrhythm Electrophysiol. 2011;4:352\u201361. PubMed PMID: 21493962.   \nOlson TM, Alekseev AE, Moreau C, Liu XK, Zingman LV, Miki T, Seino S, Asirvatham SJ, Jahangir A, Terzic A. KATP channel mutation confers risk for vein of Marshall adrenergic atrial fbrillation. Nat Clin Pract Cardiovasc Med. 2007;4:110\u20136. PubMed PMID: 17245405.   \n",
      "token_count": 458,
      "sentence_count": 28
    },
    {
      "id": "rws_txt_41",
      "contents": "Sy RW, van der Werf C, Chattha IS, Chockalingam P, Adler A, Healey JS, Perrin M, Gollob MH, Skanes AC, Yee R, Gula LJ, Leong-Sit P, Viskin S, Klein GJ, Wilde AA, Krahn AD. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation. 2011;124:2187\u201394. PubMed PMID: 22042885.   \nTardo DT, Peck M, Subbiah RN, Vandenberg JI, Hill AP. Te diagnostic role of T wave morphology biomarkers in congenital and acquired long QT syndrome: a systematic review. Ann Noninvasive Electrocardiol. 2023;28:e13015. PubMed PMID: 36345173.   \nTester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005;2:507\u201317.",
      "token_count": 241,
      "sentence_count": 14
    },
    {
      "id": "arvd_txt_19",
      "contents": " A study in younger individuals suggested that cardiac MRI was more sensitive than echocardiogram but that it was still unusual, even with cardiac MRI, to identify ARVC in children before age ten years [Etoom et al 2015]. \nIn children younger than age 18 years. Te 2010 Task Force Criteria [Marcus et al 2010] should be used with caution, as many of the EKG diagnostic criteria are a normal fnding in children, such as inverted T waves in right precordial leads (V1, V2, and V3) [Te Riele et al 2021]. Cardiac MRI has been shown to have a better positive predictive value (and especially data from echocardiogram and cardiac MRI combined) [Steinmetz et al 2018, Te Riele et al 2021]. \nRecommendations for Medical and Surgical Management of ARVC \nAfected individuals should be monitored by a cardiologist who is knowledgeable about ARVC. Management of individuals with ARVC is complicated by its variable course and the limited specifcity of clinical fndings to predict arrhythmia risk. Management should be individualized and based on the specifc results of detailed clinical and genetic investigation. \nGene-Specific Management Recommendations \nDSP. Because of the risk of lef ventricular dysfunction associated with $D S P$ pathogenic variants [Smith et al 2020], management for individuals with $D S P$ -related ARVC should address monitoring and management for  lef ventricular dysfunction, including guideline-directed therapy [Towbin et al 2019, Heidenreich et al 2022]. \nGeneral Management Recommendations for ARVC \nTreatment recommendations for ARVC can be found in an international task force consensus statement [Corrado et al 2015]. Additional guidance is found in the American College of Cardiology / American Heart Association / Heart Rhythm Society (AHA/ACC/HRS) guideline for management of individuals with ventricular arrhythmias and the prevention of sudden cardiac death [Al-Khatib et al 2018] and in an updated Heart Rhythm Society guideline for arrhythmogenic cardiomyopathy [Towbin et al 2019]. \n\u2022 Management is focused on prevention of syncope, cardiac arrest, and sudden death (see Prevention of Primary Manifestations).   \n",
      "token_count": 470,
      "sentence_count": 14
    },
    {
      "id": "fabry_txt_16",
      "contents": " Males and females with cardiac disease are asymptomatic during most of their lives and typically present in the sixth to eighth decade of life with LVH, HCM, conduction disturbances, and arrhythmias. Screening of males with \"late-onset\" HCM found that $6.3\\%$ who were diagnosed at or afer age 40 years and $1.4\\%$ of males who were diagnosed before age 40 years had Fabry disease confrmed by identifcatio n of low $\\mathfrak{a}$ -Gal A enzyme activity and a GLA hemizygous pathogenic variant [Sachdev et al 2002]. Magnetic resonance imaging of the heart typically shows late enhancement of the posterior wall with gadolinium refectin g posterior wall fbrosis demonstrated in postmortem specimens [Moon et al 2003]. Te incidence of cardiac complications is similar in individuals with the atypical Fabry cardiac variant and individuals with classic Fabry disease [Patel et al 2015]. Females may develop myocardial fbrosis without apparent LVH [Mundigler et al 2011]. \nIndividuals with the cardiac variant exhibit mild-to-moderate proteinuria with normal renal function for age. Renal pathology is limited to glycosphingolipid deposition in podocytes, which is presumably responsible for their proteinuria. Tey generally do not develop kidney failure except in the presence of an additional etiology or risk factor and kdiney biopsy should be considered for all individuals with a pathogenic variant predictive of late-onset cardiac disease who develop renal impairment. \nRenal manifestations. Renal variants were identifed among individuals of Japanese ancestry on chronic hemodialysis in whom ESKD had been misdiagnosed as chronic glomerulonephritis [Nakao et al 2003]. Of note, fve of the six individuals did not have angiokeratoma, acroparesthesia, hypohidrosis, or corneal opacities, but did have moderate-to-severe LVH. Tese observations indicated that the early symptoms of classic Fabry disease may not occur in individuals with the renal variant who develop renal insufciency, and that the renal variant may be underdiagnosed.",
      "token_count": 479,
      "sentence_count": 14
    },
    {
      "id": "thompson_thompson_genetics_8th_edition_medicoscompanion_com_txt_755",
      "contents": " The first-line screening consists of clinical testing with cardiac imaging and electrocardiography to identify phenotypepositive relatives. Genetic testing can also be used to identify family members at risk for developing disease who do not have LVH. \nNo treatments to prevent disease development or to reverse established manifestations currently exist. The treatment of manifestations includes medical management of diastolic dysfunction, medical or surgical management of ventricular outflow obstruction, restoration and maintenance of sinus rhythm in those with atrial fibrillation, implantable cardioverter-defibrillator in survivors of cardiac arrest and those at high risk for cardiac arrest, medical treatment for heart failure, and consideration for cardiac transplantation when necessary. The prevention of secondary complications includes consideration of anticoagulation in those with persistent or paroxysmal atrial fibrillation to reduce the risk for thromboembolism; consideration of antibiotic prophylaxis when necessary; and during the pregnancy of a woman with HCM, care by an experienced cardiologist and obstetrician trained in high-risk obstetrics. Patients should avoid competitive endurance training, burst activities (e.g., sprinting), intense isometric exercise (e.g., heavy weight lifting), dehydration, hypovolemia (i.e., use diuretics with caution), and medications that decrease afterload (e.g., angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers, and other direct vasodilators). But the consensus recommendations from the 36th Bethesda Conference do not exclude individuals carrying pathogenic mutations but without manifestations of the disease from sports. \n\nINHERITANCE RISK \nHCM follows autosomal dominant inheritance with variable expressivity and incomplete, age-related penetrance; each first-degree relative of an affected patient has a $50\\%$ chance of carrying the mutation and potentially developing HCM. Alternatively, sporadic cases may be due to de novo mutations in the proband but absent from the parents. \nDisease prevention based on genetic testing is currently available in the form of assisted reproduction using preimplantation genetic diagnosis (PGD) or prenatal diagnosis with pregnancy termination in the event of an affected fetus (see Chapter 17). \nQUESTIONS FOR SMALL GROUP DISCUSSION \n1. Name other disorders that show age-related penetrance.",
      "token_count": 496,
      "sentence_count": 17
    },
    {
      "id": "cav-Table2_txt_0",
      "contents": "Title: Caveolinopathies GeneReview Table 2   \nAuthors: Bruno C, Sotgia F, Gazzerro E, Minetti C, Lisanti MP   \nDate: September 2012   \nNote: The following information is provided by the authors listed above and has not been reviewed by GeneReviews staff. \nReferences \nde Paula F, Vainzof M, Bernardino AL, McNally E, Kunkel LM, Zatz M. Mutations in the caveolin-3 gene: When are they pathogenic? Am J Med Genet. 2001;99:303-7.   \nFee DB, So YT, Barraza C, Figueroa KP, Pulst SM. Phenotypic variability associated with Arg26Gln mutation in caveolin3. Muscle Nerve. 2004;30:375-8.   \nHayashi T, Arimura T, Ueda K, Shibata H, Hohda S, Takahashi M, Hori H, Koga Y, Oka N, Imaizumi T, Yasunami M, Kimura A. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun. 2004;313:178-84.   \nKubisch C, Ketelsen UP, Goebel I, Omran H. Autosomal recessive rippling muscle disease with homozygous CAV3 mutations. Ann Neurol. 2005;57:303-4.   \nMcNally EM, de Sa Moreira E, Duggan DJ, Bonnemann CG, Lisanti MP, Lidov HG, Vainzof M, PassosBueno MR, Hoffman EP, Zatz M, Kunkel LM. Caveolin-3 in muscular dystrophy. Hum Mol Genet. 1998;7:871-7.   \nReijneveld JC, Ginjaar IB, Frankhuizen WS, Notermans NC. CAV3 gene mutation analysis in patients with idiopathic hyper-CK-emia. Muscle Nerve. 2006;34:656-8. ",
      "token_count": 444,
      "sentence_count": 27
    },
    {
      "id": "tfap_txt_7",
      "contents": "Cardiac amyloidosis, mainly characterized by progressive cardiomyopathy, has been associated with more than two thirds of TTR pathogenic variants (see Table 6) [Nakazato 1998, Benson 2001, Saraiva 2001, Connors et al 2003, Hattori et al 2003, Benson & Kincaid 2007]. In some families with specifc TTR variants, such as p.Asp38Asn, p.Val40Ile, p.Pro44Ser, p.Ala65Tr, p.Ala65Ser, p.His76Arg, p.Gly77Arg, p.Ile88Leu, p.Ala101Tr, p.Ala101Val, p.His108Arg, p.Glu112Lys, p.Arg123Ser, p.Leu131Met, or p.Val142Ile, cardiomyopathy without peripheral neuropathy is a main feature of the disease. \nCardiac amyloidosis is usually late onset. Most individuals develop cardiac symptoms afer age 50 years; cardiac amyloidosis generally presents with restrictive cardiomyopathy. Te typical electrocardiogram shows a pseudoinfarction pattern with prominent Q wave in leads II, III, $\\phantom{}_{\\mathsf{a}}\\mathrm{V}_{\\mathrm{F}},$ and $\\mathrm{V}_{1^{-}}\\mathrm{V}_{3}$ , presumably resulting from dense amyloid deposition in the anterobasal or anteroseptal wall of the lef ventricle. Te echocardiogram reveals lef ventricular hypertrophy with preserved systolic function. Te thickened walls present \"a granular sparkling appearance.\" \nAmong the variants responsible for cardiac amyloidosis, p.Val142Ile is notable for its prevalence in African Americans. Approximately $3.0\\%{-3.9\\%}$ of African Americans are heterozygous for p.Val142Ile [Yamashita et al 2005]. Te high frequency of p.",
      "token_count": 454,
      "sentence_count": 27
    },
    {
      "id": "hyper-card_txt_2",
      "contents": "Individuals with HCM are at an increased risk for atrial fbrillation (AF), which can have signifcant morbidity due to increased risk of thromboembolism and symptomatic deterioration. Te prevalence of AF increases with age and duration of disease. Te overall prevalence of AF in individuals with HCM is ${\\sim}20\\%$ , but prevalence is ${\\sim}60\\%$ by age 60 years for individuals diagnosed with HCM by age 40 years [Elliott et al 2014, Ho et al 2018]. In individuals with HCM and AF the prevalence of thromboembolic complications has been estimated at $27\\%$ [Elliott et al 2014]. \nApproximately $5\\%{-}10\\%$ of individuals with HCM progress to end-stage disease with impaired systolic function and, in some cases, lef ventricular dilatation and regression of LVH. Te annual mortality rate in individuals with end-stage disease is estimated at $11\\%$ [Harris et al 2006] and cardiac transplantation may be required. \nSudden cardiac death (SCD), most likely related to ventricular tachycardia / ventricular fbrillation, is an important but relatively rare consequence of HCM. \n\u2022 In a large cohort of individuals with HCM, $6\\%$ experienced sudden death, resuscitated cardiac arrest, or appropriate ICD therapy [Ho et al 2018]. \u2022 SCD may be the frst manifestation of disease [Maron et al 2000, Finocchiaro et al 2019]. \n\u2022 HCM is a well-described cause of SCD in competitive athletes in the US [Maron 2003], although more recent studies report a decline in prevalence $(\\sim\\!5\\%\\!-\\!14\\%)$ [Eckart et al 2011, Harmon et al 2014, Bagnall et al 2016].   \n\u2022 Whereas sudden death occurs most ofen in adolescents or young adults, it may occur at any age and the risk persists throughout life. \nLife span. Compared to the US general population, the mortality rate in individuals with HCM is approximately threefold higher, but the mortality rate in younger individuals with HCM, ages 20-29, is as much as fourfold higher than expected.",
      "token_count": 488,
      "sentence_count": 13
    },
    {
      "id": "hgps_txt_8",
      "contents": " Sequential manifestations of cardiovascular decline include impaired relaxation of the heart muscle, followed by ventricular hypertrophy. Tis may occur in the setting of heart valve thickening or stenosis, or with hypertension that is ofen labile. Mitral and aortic valve abnormalities, including calcifcation, stenosis, and regurgitation, usually develop in the second decade of life. Aortic gradient increases exponentially with time at later stages of disease, portending critical aortic stenosis [Gordon et al, unpublished data]. \nSystolic dysfunction is usually present in the setting of advanced disease, with or without identifed coronary vascular insufciency. Clinical symptoms of angina, dyspnea on exertion, or overt heart failure appear as late fndings in the course of disease. \nTransient ischemic attacks, silent strokes, or symptomatic strokes have occurred as early as age four years [Silvera et al 2013]. Strokes can occur at any brain site and, therefore can lead to a variety of physical limitations \nand/or cognitive decline. Partial and complete carotid artery blockages can occur from plaque formation.   \nDespite underlying vascular disease, most children do not have clinically identifed strokes. \nRaynaud phenomenon in fngers occurs in a minority of afected individuals. \nWithout lonafarnib treatment, death typically occurs as a result of complications of cardiac or cerebrovascular disease. More than $80\\%$ of deaths are due to heart failure and/or myocardial infarction, most ofen between ages six and 20 years, with an average life span of approximately 14.5 years [Gordon et al 2014, Gordon et al 2018a]. Average life span is extended to approximately 17-19.5 years with lonafarnib therapy, with similar cause of death. \nOphthalmologic. Nocturnal lagophthalmos (the inability to fully close the eyes during sleep) is common. As a result, corneal dryness and clouding can occur. In a minority of individuals, corneal ulceration occurs due to exposure keratitis [Mantagos et al 2017]. \nHearing.",
      "token_count": 458,
      "sentence_count": 21
    },
    {
      "id": "acpp_txt_6",
      "contents": "Ventricular arrhythmias including bidirectional ventricular tachycardia (VT), polymorphic VT, and multifocal premature ventricular contractions may be asymptomatic, or may manifest (most commonly) as palpitations. Less common symptomatic presentations include syncope, cardiac arrest, or sudden death [Andelfnger et al 2002, Tristani-Firouzi et al 2002, Donaldson et al 2003]. While the EKG may reveal a long QTc (LQT) interval, characteristic T-U patterns including enlarged U waves, a wide T-U junction, and prolonged terminal T-wave downslope distinguish ATS from other LQT syndromes [Zhang et al 2005, Haruna et al 2007]. A large case series found no signifcant diference in the incidence of ventricular tachyarrhythmias between individuals with typical and atypical presentations of ATS [Kimura et al 2012]. A retrospective multicenter French study of 36 individuals with ATS followed for an average of 9.5 years reported no deaths in follow up; four individuals experienced syncope and one individual had a non-fatal cardiac arrest [Delannoy et al 2013]. \nDilated cardiomyopathy was observed in two of three afected individuals in a single kindred with pathogenic variant p.Arg218Trp [Schoonderwoerd et al 2006]. Additionally, cardiomyopathy was documented and reversed by treatment with fecainide in an individual with pathogenic variant p.Arg67Trp [Pellizz\u00f3n et al 2008], and reversed by bisoprolol in another individual with typical clinical features of ATS and novel variant p.Leu222Ser [Rezazadeh et al 2016]. Tese reports suggest that dilated cardiomyopathy is a secondary phenotype as a consequence of chronic tachycardia rather than a primary phenotypic manifestation. Additional study is needed to further delineate this clinical feature. \n",
      "token_count": 437,
      "sentence_count": 13
    },
    {
      "id": "brugada_txt_31",
      "contents": " PubMed PMID: 32248082.   \nMaury P, Couderc P, Delay M, Boveda S, Brugada J. Electrical storm in Brugada syndrome successfully treated using isoprenaline. Europace. 2004;6:130\u20133. PubMed PMID: 15018871.   \nMeregalli PG, Tan HL, Probst V, Koopmann TT, Tanck MW, Bhuiyan ZA, Sacher F, Kyndt F, Schott JJ, Albuisson J, Mabo P, Bezzina CR, Le Marec H, Wilde AA. Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm. 2009;6:341\u20138. PubMed PMID: 19251209.   \nMills AT, Dasan S, Wan A. Brugada syndrome: syncope in the younger patient and the risk of sudden cardiac death. Emerg Med J. 2005;22:604\u20136. PubMed PMID: 16046779.   \nMiyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol. 1996;27:1061\u2013 70. PubMed PMID: 8609322.   \nMorita H, Kusano KF, Miura D, Nagase S, Nakamura K, Morita ST, Ohe T, Zipes DP, Wu J. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation. 2008;118:1697\u2013704. PubMed PMID: 18838563.   \nMorita H, Zipes DP, Wu J. Brugada syndrome: insights of ST elevation, arrhythmogenicity, and risk stratifcatio n from experimental observations. Heart Rhythm. 2009;6:S34\u201343. PubMed PMID: 19880072.   \nNakazato Y, Suzuki T, Yasuda M, Daida H.",
      "token_count": 470,
      "sentence_count": 31
    }
  ],
  "scan_analyses": [
    {
      "scan_type": "ECG",
      "scan_date": "2025-03-25T09:09:28.833517",
      "file_name": "norm.png",
      "description": "ECG Scan for Patient",
      "analysis": "Okay, let\u2019s analyze this ECG. Here's a detailed breakdown of what I see, incorporating relevant observations and potential concerns:\n\n**Overall Impression:**\n\nThe ECG shows a sinus rhythm, but there are several concerning findings that warrant immediate attention and further investigation.  The most prominent abnormality is a significant left ventricular hypertrophy (LVH). \n\n**Detailed Analysis \u2013 Waveform by Waveform:**\n\n* **Rate:** The heart rate appears to be approximately 75-80 beats per minute. This is within the normal range.\n* **Rhythm:** The rhythm is regular, indicating sinus rhythm.\n* **P Waves:** The P waves are present and generally upright in leads I, II, aVL, and V1-V6. However, they appear somewhat peaked and notched, particularly in V1 and V6, suggesting some degree of ventricular pre-excitation (WPW pattern, though not definitively confirmed).\n* **PR Interval:** The PR intervals are prolonged, consistently greater than 0.20 seconds (approximately). This prolongation is a key indicator of LVH.\n* **QRS Complex:** This is where the most significant abnormalities are present.\n    * **Width:** The QRS complexes are wide, consistently greater than 0.12 seconds. This is a hallmark of LVH.\n    * **Morphology:** The QRS complexes are predominantly positive in leads V1-V6, indicating right ventricular involvement. The Q waves are present but not excessively deep.\n* **ST Segment:** The ST segments are elevated, particularly in leads V1-V6, and in some cases, there is ST-segment depression. This is consistent with myocardial ischemia or injury.\n* **T Waves:** The T waves are generally inverted in the precordial leads (V1-V6), further supporting the presence of myocardial ischemia.\n* **QT Interval:** The QT intervals appear normal.\n\n**Specific Findings and Observations:**\n\n1. **Left Ventricular Hypertrophy (LVH):** This is the most significant finding. The prolonged PR intervals, wide QRS complexes, and ST-segment changes all point to LVH. The prominence of the Q waves in V1-V6 suggests the hypertrophy is more pronounced on the right side of the heart as well.\n\n2. **Possible Ventricular Pre-excitation (WPW):** The slightly peaked and notched P waves, particularly in V1 and V6, raise the possibility of a pre-excitation"
    }
  ],
  "analysis_date": "2025-03-25T09:26:03.374926",
  "created_at": "2025-03-25T09:26:03.374931"
}